Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs

Samankaltaisia teoksia

• Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
  Tekijä: Deodhar, Malavika, et al.
  Julkaistu: (2020)
• Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy
  Tekijä: Sweilem B. Al Rihani, et al.
  Julkaistu: (2020-08-01)
• Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy
  Tekijä: Al Rihani, Sweilem B., et al.
  Julkaistu: (2020)
• ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
  Tekijä: Michaud, Veronique, et al.
  Julkaistu: (2020)
• Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study
  Tekijä: Smith, Matt K., et al.
  Julkaistu: (2021)